The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases

TNF-related apoptosis-inducing ligand (TRAIL) was originally discovered, almost 20 years ago, for its ability to kill cancer cells. More recent evidence has described pleiotropic functions, particularly in the cardiovascular system. There is potential for TRAIL concentrations in the circulation to act as prognostic and/or diagnostic factors for cardiovascular diseases (CVD). Pre-clinical studies also describe the therapeutic capacity for TRAIL signals, particularly in the context of atherosclerotic disease and diseases of the myocardium. Because diabetes mellitus significantly contributes to the progression and pathogenesis of CVDs, in this review we highlight recent evidence for the prognostic, diagnostic, and therapeutic potential of TRAIL signals in CVDs, and where relevant, the impact of diabetes mellitus. A greater understanding of how TRAIL signals regulate cardiovascular protection and pathology may offer new diagnostic and therapeutic avenues for patients suffering from CVDs.

Automated summary

TNF-related apoptosis-inducing ligand (TRAIL) was originally discovered for its ability to kill cancer cells, but recent evidence suggests its pleiotropic functions in the cardiovascular system. Circulating TRAIL concentrations have potential as prognostic and/or diagnostic factors for cardiovascular diseases (CVD). Pre-clinical studies show therapeutic capacity for TRAIL signals in atherosclerotic disease and diseases of the myocardium. This review highlights the prognostic, diagnostic, and therapeutic potential of TRAIL signals in CVDs, including the impact of diabetes mellitus.